Sign In
Buy GMAB
$23.88
+0.0300 (+0.126%)
At Close: Jun 03, 2026
GMAB or TECH: Which Is the Better Value Stock Right Now?
06:04pm, Tuesday, 09'th Jan 2024
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Genmab A/S Sponsored ADR (GMAB) and Techne (TECH). But which of these two companies is the best opti
Genmab to Present at the 42nd Annual J.P. Morgan Healthcare Conference
09:52am, Tuesday, 02'nd Jan 2024
Media Release COPENHAGEN, Denmark; January 2, 2024 Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 42nd Annual J.P. Morgan Health
5 Biotech Acquisition Targets To Accumulate In 2024
01:05pm, Thursday, 21'st Dec 2023
Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provid
7 Must-Buy Stocks That Are on Ridiculous Discount Now
11:57pm, Monday, 13'th Nov 2023
Given that this may be the year of artificial intelligence, it's no surprise that while certain enterprises have hogged the spotlight, astute investors also enjoy compelling opportunities regarding st
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
10:01pm, Thursday, 09'th Nov 2023
Amid some rising questions for the economy, value-seeking investors may want to consider underappreciated biotech stocks. As a sector that, while not immune to broader pressures, generally manages to
Genmab to Present at Jefferies London Healthcare Conference
05:00am, Thursday, 09'th Nov 2023
Media Release COPENHAGEN, Denmark; November 9, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer, Jan van de Winkel, Ph.D. and Chief Financial Officer, Anthony Pagano wil
Zai Lab ADR surges after Seagen, Genmab release cervical cancer treatment results
08:12am, Tuesday, 05'th Sep 2023
Zai Lab Ltd.'s American depositary receipts ZLAB, +2.47% jumped 14% premarket on Tuesday after Seagen Inc. SGEN, +0.89% and Genmab A/S GMAB, +0.24% announced that Tivdak, their treatment for cervical
Genmab, Seagen say Tivdak cervical cancer trial met overall survival endpoint
05:33pm, Monday, 04'th Sep 2023
Genmab A/S , and Seagen Inc on Monday said that the Phase III trial of Tivdak in recurrent or metastatic cervical cancer patients on or after front-line therapy met its primary endpoint of overall sur
Genmab Is Down To Attractive Levels
11:17am, Wednesday, 30'th Aug 2023
Genmab's stock is down 15% since late 2022 highs but the company and its partners continue to execute well. The approval and launch of Epkinly for the treatment of DLBCL is a significant milestone for
Genmab to Present at Morgan Stanley 21st Annual Global Healthcare Conference
10:06am, Monday, 28'th Aug 2023
Media Release COPENHAGEN, Denmark; August 28, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan van de Winkel, Ph.D. and Chief Financial Officer Anthony Pagano will p
3 Biotech Stocks You Better Be Buying on Each and Every Dip
07:00am, Thursday, 27'th Jul 2023
Biotechnology is one of the most exciting and innovative sectors in the market, offering investors the potential for high returns coupled with groundbreaking discoveries. However, due to regulatory hu
3 Biotech Stocks That AI is Loving in July
07:51am, Wednesday, 12'th Jul 2023
Artificial intelligence (AI) has become an invaluable tool for investors seeking opportunities in the stock market. Its ability to analyze large amounts of data and recognize patterns makes it an ally
Could This New Drug Be a Blockbuster for These 2 Pharma Collaborators?
09:30am, Sunday, 02'nd Jul 2023
In clinical trials, epcoritamab proved highly effective in treating a certain kind of lymphoma. The cancer drug, developed jointly by AbbVie and Genmab, has a huge potential market.
Genmab: Epkinly's Approval Not Big Enough Needle-Mover (Neutral)
10:05am, Thursday, 29'th Jun 2023
Genmab's stock has seen negative price action despite the FDA approval of its drug, Epcoritamab, for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The market has already priced in the app
Genmab to Participate in a Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference
02:00am, Tuesday, 06'th Jun 2023
Media Release COPENHAGEN, Denmark; June 6, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Goldman Sachs 44 th
